Shares of other companies:
April 27, 2024 Alphabet and Microsoft’s AI Investments Yield Strong Returns
April 26, 2024 Top 10 High Dividend Yield Stocks
Tesla Q1: Model 2 Could Be Their Model T
April 25, 2024
April 23, 2024 Maximizing Profits: When is the Right Time to Sell Your Business?
Selling a business can be a momentous decision filled with many considerations and uncertainties. As an entrepreneur, this also symbolizes your years of…
April 12, 2024 Improve Your Financial Status: A How-To Guide
Navigating through the complexities of personal finance can often feel like walking through a maze blindfolded. This guide is crafted especially for you,…
April 12, 2024 How ZIM Integrated Container Tracking is Revolutionizing Global Trade
Have you ever wondered how your online shopping packages get to you? A big part of the answer is ZIM Integrated Container Tracking.…
March 15, 2024 6 Best Growth Stocks To Buy Now According to Metatrader 5
One of the reasons investors prefer growth stocks is that they are expected to perform better than other companies in terms of sales…
IMMX Stock News and Mentions of Immix Biopharma, Inc. Stocktwits
Updated: April 28, 2024 (09:14)
Sector: Healthcare
Welcome to PandaPulse, innovative analytical stock market observer, where the latest news and stocktwits meets in-depth investor relations insights. Dive into our real-time sentiment analysis to gauge the mood of the markets and arm yourself with key information that resonates with both savvy investors and casual traders.
We meticulously analyze the sentiment trend in each article for the last 60 days where Immix Biopharma Company is mentioned. We assess its relevance and importance to carry out an overall sentiment valuation of Immix Biopharma, Inc. (IMMX).
You can view the trend designation for each individual article below. We use this data to compile indicators into one comprehensive sentiment value, which represents the current information agenda about the Immix Biopharma stocks.
Please wait, while the data is preparing...
General evaluation of the current information agenda's sentiments
Agenda Trend
Analyzed articles
News and Mentions of Immix Biopharma, Inc. (IMMX)
April 18, 2024 (13:32) / "GlobeNewswire" (by Inc.)
Immix Biopharma on Track to Dose NXC-201 Patients in United States
• Scheduling U.S. site initiation visits April and May 2024 • On track to dose relapsed/refractory AL Amyloidosis patients with CAR-T NXC-201 at New York City lead site and other leading U.S. sites mid-2024
In Article Trend: Neutral
April 15, 2024 (13:36) / "GlobeNewswire" (by Inc.)
Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 27th Annual Meeting of the American Society of Gene and Cell Therapy ( ASGCT )
LOS ANGELES, April 15, 2024 ( GLOBE NEWSWIRE ) -- Immix Biopharma, Inc. ( Nasdaq: IMMX ) ( "ImmixBio", "Company", "We" or "Us" or "IMMX" ) , a clinical-stage biopharmaceutical company trailblazing cell therapies in AL Amyloidosis and other autoimmune diseases, today announced that updated ...
In Article Trend: Neutral
April 15, 2024 (13:36) / "Benzinga" (by Globe Newswire)
Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 27th Annual Meeting of the American Society of Gene and Cell Therapy ( ASGCT ) - Immix Biopharma ( NASDAQ:IMMX )
Updated clinical data for next-generation CAR-T NXC-201 in relapsed/refractory AL amyloidosis will be presented in Baltimore May 7-11, 2024 LOS ANGELES, April 15, 2024 ( GLOBE NEWSWIRE ) -- Immix Biopharma, Inc.
In Article Trend: Neutral
March 20, 2024 (13:46) / "GlobeNewswire" (by Immix Biopharma)
Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial
LOS ANGELES, CA, March 20, 2024 ( GLOBE NEWSWIRE ) -- Immix Biopharma, Inc. ( Nasdaq: IMMX ) ( "ImmixBio", "Company", "We" or "Us" or "IMMX" ) , a clinical-stage biopharmaceutical company trailblazing cell therapies in AL Amyloidosis and other autoimmune diseases, today announced Memorial Sloan ...
In Article Trend: Neutral
March 5, 2024 (14:35) / "GlobeNewswire" (by Immix Biopharma)
Immix Biopharma Announces "Be Proactive in AL" AL Amyloidosis Awareness Initiative
Hear from the ~30,000 relapsed or refractory AL Amyloidosis patients in the United States today in their own words Hear from the ~30,000 relapsed or refractory AL Amyloidosis patients in the United States today in their own words ...
In Article Trend: Neutral
Related stocks from Healthcare sector
This website uses cookies to ensure you get the best experience on our website